By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cancer Therapy Gets Small for Humans — and Animals
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Radiology > Cancer Therapy Gets Small for Humans — and Animals
DiagnosticsRadiology

Cancer Therapy Gets Small for Humans — and Animals

Michael Lewis
Michael Lewis
Share
4 Min Read
Image
SHARE

For many decades, treatment of cancer has relied on three major modalities: surgery, chemotherapy, and radiotherapy. As a radiation oncology researcher, I am fortunate to be at the University of Missouri, where considerable emphasis has been placed on advancements among these three areas in targeted nanomedicine. Our university is the only one in the nation with a school of medicine, a college of veterinary medicine, and nuclear reactor powerful enough for specialized applications in cancer radiotherapy.

For many decades, treatment of cancer has relied on three major modalities: surgery, chemotherapy, and radiotherapy. As a radiation oncology researcher, I am fortunate to be at the University of Missouri, where considerable emphasis has been placed on advancements among these three areas in targeted nanomedicine. Our university is the only one in the nation with a school of medicine, a college of veterinary medicine, and nuclear reactor powerful enough for specialized applications in cancer radiotherapy. We are working on an initiative called One Health, One Medicine — the convergence of human and animal health care.Image

My experience in nanomedicine in research is comparatively new. I came to UM in 2000 as a member of the MU Mission Enhancement program — a forerunner to One Health, One Medicine — working in the Department of Veterinary Medicine and Surgery, to facilitate interdisciplinary research involving laboratory scientists and veterinarians. The idea was to bring new faculty members on board to build on the strengths of each campus, with a major emphasis on the life sciences.

Over the past two months, I have been working with Dave Robertson, the Associate Director for Research at MU’s Research Reactor. We have developed new nanoparticles containing a radioisotope of the element lutetium and attached to tumor-targeting peptides, supported by awards from the National Cancer Institute and the Department of Veterans Affairs and using facilities at the Harry S. Truman Memorial Veterans’ Hospital in Columbia, Missouri. We hypothesized that our nanoparticles contain large quantities of radioactive lutetium, packing a potent punch for tumor cell killing, as well as having several copies of the targeting peptide for enhanced delivery.

More Read

What To Know About Melanoma Prevention Year-Round
“Hot Chemotherapy” Gaining Steam
SaaS Firm Crowdfunds “People-Focused” Image Sharing
RSNA 2012: “Chemo Brain” Is For Real
Prognostic Scoring Analysis System Can Tell How Long Cancer Patients Have to Live

In a short time, we demonstrated that these nanoparticles selectively accumulate in lymphoma tumor cells. Our findings forward the mission and goals of One Health, One Medicine in comparative oncology, a field involving the study of cancer in animals (primarily companion animals), with direct translation of the results of those studies to human cancer diagnosis and treatment. With this promising development, we plan to study lymphoma-bearing mice, then pet dogs with lymphoma, and hopefully one day, clinical trials in human patients.

In the field of radiopharmaceutical sciences, there is an intimate relationship between diagnosis and treatment using radiopharmaceuticals. Take, for example, small lymphocytic lymphoma/chronic lymphocytic leukemia — an incurable form of cancer in a large majority of cases calling for innovative treatments. Nanoparticle radiopharmaceuticals represent such potential treatments. We hope our findings raise awareness of interdisciplinary science by bringing laboratory scientists and clinicians together to make new discoveries in collaboration.

image: medtech/shutterstock

Original Post

 
TAGGED:cancerOne Health
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

The New York Times, Aspirin and Melanoma

March 17, 2013

Andrew Schorr Reporting from EHA 2014

June 28, 2014

Don’t Regulate DTC Genetic Testing

April 27, 2011

Kiosk Offers Health Assessment

March 23, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?